Core Viewpoint - The company has experienced a significant decrease in investment income year-to-date due to factors such as declining market interest rates, prompting it to implement various measures to enhance operational performance [2] Group 1: Operational Strategies - The company is focusing on cost control, production optimization, and market expansion to improve its performance [2] - It aims to diversify its product structure to dilute fixed costs and create new profit sources [2] - The company is reducing energy costs through solar power generation and equipment energy-saving renovations [2] Group 2: Production and R&D Enhancements - There is a continuous improvement in production line automation and personnel configuration to better support the industrialization of new products [2] - The company has made progress in basic research and process optimization, with an increased conversion rate of erythritol [2] - A systematic patent layout has been established around new products [2] Group 3: Market Expansion - The company is actively expanding into domestic markets and emerging markets in Southeast Asia, India, and the Middle East [2] - Incremental demand in certain regions is providing a hedge against fluctuations in the European and American markets [2]

Core Viewpoint - Sanwei Biotech is actively advancing the industrialization and market expansion of diversified products, including allulose, tagatose, mannitol, and others, to enhance its product structure and overall business resilience [2]. Product Development - Allulose: The company has launched a production capacity of 10,000 tons, with an additional 10,000 tons under construction. Sales from January to September have shown significant year-on-year growth, meeting the needs of domestic clients like Nayuki Tea and steadily increasing overseas demand [2]. - Tagatose: Approved as a new food ingredient in China since 2014 and recognized in multiple countries, the company is optimizing production processes to reduce costs and enhance market potential. Tagatose and allulose both possess health benefits related to blood sugar control and gut microbiota regulation, with ongoing efficacy research in collaboration with Binzhou Medical University [2]. - Mannose: The company has small-scale production capabilities and is in the process of applying for domestic and overseas certifications. Mannose is gaining attention for its applications in medical research and health nutrition [2]. - Mannitol: The company has developed a cost advantage through new production processes and plans to gradually introduce it to the market [2]. - Reb M: The market acceptance of Reb M is increasing through continuous promotion, and the company has also developed sweet tea glycosides from regular steviol glycosides, with mature processing technology [2]. - Cosmetic Ingredients: The company leverages its synthetic biology technology to develop glycerol glycosides, ascorbic acid glucosides, and alpha arbutin, expanding its product applications in the daily chemical sector [2]. Strategic Goals - The gradual advancement of these products will help the company maintain its core competitiveness in erythritol while enhancing product diversity and improving overall business stability and risk resistance [2].

Core Viewpoint - Sanwei Biotech announced its commitment to customer-driven innovation in the industrial application of functional sugars, particularly focusing on the growing demand for allulose in international markets [2] Group 1: Allulose Market - The demand for allulose from American clients, including companies like Tyle, is robust, with increasing acceptance in Australia and Southeast Asia [2] - The limited number of domestic manufacturers with production licenses for allulose provides a competitive advantage for the company to capture market share [2] Group 2: Tagatose Market - Japanese downstream companies are accelerating their investments in tagatose, with clients visiting the company to assess production capacity and quality systems for stable raw material supply [2] - A well-known Japanese enterprise is planning to develop food products containing mannose and is researching regulatory registration for mannose based on the company's products [2] - Some collaborations are still in the communication and verification stages, with the company aiming to advance new product launches steadily under compliance [2]

Core Viewpoint - The company, San Yuan Bio, announced that the price of erythritol exported to the U.S. remains stable at over $1 per kilogram, with no significant changes observed [2] Group 1: Company Actions - The company has engaged a professional legal team to participate in the U.S. anti-dumping investigation and is actively providing feedback on the investigation procedures and basis for rulings [2] - The company is monitoring the progress of the investigation and related policy changes, seeking reasonable development opportunities within legal compliance [2] Group 2: Market Context - U.S. clients have submitted objections to the U.S. Department of Commerce regarding organic erythritol, blended sugars, and non-GMO erythritol products that are not produced by domestic companies during the investigation period [2]

Core Viewpoint - The company emphasizes that the industry generally operates on a sales-based production model, maintaining only necessary inventory to balance production rhythm, and there is no significant inventory buildup due to anti-dumping investigations [2] Group 1: Industry Insights - The industry typically maintains minimal inventory levels, focusing on balancing production with sales demand [2] - There is no indication of excessive inventory accumulation related to anti-dumping investigations within the industry [2] Group 2: Company Strategy - The company is actively implementing a pricing strategy to enhance customer collaboration and market expansion while ensuring cost control and maintaining reasonable price margins [2] - The current market price of erythritol is at a low point, and the company is working to strengthen its product competitiveness and sales volume [2]

Core Insights - On November 24, a total of 17 companies were investigated by institutions, with 10 companies being surveyed by funds, indicating a strong interest in specific stocks [1] - Among the surveyed companies, 6 attracted more than 5 funds, with Crystal Morning Technology being the most popular, receiving attention from 35 funds [1] - The total market capitalization of the surveyed A-shares includes 1 company with a market cap over 500 billion yuan, and 6 companies with market caps below 100 billion yuan [1] Company Summaries - **Crystal Morning Technology (688099)**: Received the highest interest with 35 funds participating in the survey, latest closing price at 92.72 yuan, and a 5-day price increase of 15.68% [1] - **Weili Transmission (300904)**: Attracted 19 funds, latest closing price at 69.20 yuan, with a 5-day price decrease of 2.40% [1] - **Haiyou New Materials (688680)**: Surveyed by 8 funds, latest closing price at 39.17 yuan, experiencing a significant 5-day price drop of 14.83% [1] - **Sanyuan Bio (301206)**: Engaged 7 funds, latest closing price at 27.32 yuan, with a 5-day decline of 5.07% [1] - **Dayilong (002209)**: Also received attention from 7 funds, latest closing price at 14.39 yuan, with a 5-day decrease of 5.95% [1] - **Yongdong Shares (002753)**: Participated by 5 funds, latest closing price at 8.01 yuan, with a slight increase of 3.35% over 5 days [1] - **Hengyi Petrochemical (000703)**: Surveyed by 3 funds, latest closing price at 6.96 yuan, with a 5-day decline of 7.94% [1] - **Weichai Power (000338)**: Engaged 2 funds, latest closing price at 16.60 yuan, with a 5-day decrease of 6.21% [1] - **Zhongsheng Pharmaceutical (002317)**: Attracted 1 fund, latest closing price at 24.08 yuan, with a 5-day decline of 9.20% [1] - **Meirui New Materials (300848)**: Also surveyed by 1 fund, latest closing price at 14.89 yuan, with a 5-day drop of 10.52% [1]

Summary of the Conference Call for Sanren Biological Industry and Company Overview - The conference call discusses Sanren Biological, a company involved in the production of erythritol and other sugar substitutes, particularly in the context of international trade challenges and product development strategies. Key Points and Arguments Impact of U.S. Tariffs - The U.S. imposed a preliminary anti-dumping duty of 462% on erythritol, severely hindering direct exports. Despite this, the company managed to maintain some sales through transshipment trade due to strong demand and brand recognition in the U.S. market, although sales volume decreased by 25% year-on-year from January to September [2][3][5]. Legal Actions and Market Adaptation - Some customers have filed lawsuits regarding the anti-dumping duties, which could potentially allow for legal exports if the court rules that certain blended products are exempt. The U.S. government shutdown has delayed these rulings, but a resolution is expected within the next year [2][5]. European Market Challenges - The European Union has also imposed high anti-dumping duties, leading to a halt in direct exports. The company has adjusted its product formulations to produce erythritol blends with less than 90% altritol to circumvent these tariffs, which has been gradually accepted by customers, resulting in increased demand [2][6]. Domestic Market Conditions - Domestic erythritol prices have stabilized at around $1.2 to $1.3 per kilogram, with low inventory levels across the industry. Companies are primarily producing based on sales demand, and despite price reductions for promotions, Sanren Biological has managed to maintain operational effectiveness [2][7][8]. Cost Management Strategies - The company has implemented various measures to reduce production costs, including technological improvements, energy-saving modifications, and automation. These strategies have helped mitigate the impact of anti-dumping measures from the U.S. and Europe while expanding into emerging markets in Southeast Asia, the Middle East, and South America [2][9]. New Product Development - Sanren Biological is actively developing new products such as altritol, tagatose, and cosmetic ingredients, with increasing domestic and international demand for altritol. The company has begun small-scale supply of these products and is exploring market opportunities [2][4][10][11]. Financial Considerations - The decline in bank interest rates has negatively impacted the company's financial income. However, the company plans to manage funds flexibly and explore horizontal mergers and acquisitions to enhance performance and profitability [2][14]. Future Outlook for Altritol - There is significant interest in altritol, with several companies planning large-scale production. However, the company remains cautious about large investments due to potential market oversupply and competition risks [2][15]. Resource Allocation for New Products - The company prioritizes the development of new products based on market acceptance and potential, focusing on altritol, tagatose, and various cosmetic ingredients, while ensuring efficient resource allocation [2][16]. Long-term Development Goals - Sanren Biological aims to expand its product range and contribute to the health industry through technological innovation and resource integration, striving for sustainable development and shareholder returns [2][17].

Group 1: Industry Overview and Challenges - The company is facing significant challenges due to the U.S. anti-dumping investigation, with an initial tax rate of 450.64% imposed on erythritol exports [3] - The investigation has led to a temporary supply tightness in the U.S. market, but demand remains from North America, with imports from Canada and Mexico gradually increasing [3] - The company is actively participating in the investigation process and has engaged a legal team to defend its interests [3] Group 2: Financial Performance - In Q3 2025, the company's sales revenue showed a year-on-year increase, although overseas revenue slightly decreased compared to the first half of the year [3] - Investment income has significantly decreased due to lower market interest rates, prompting the company to implement cost control and production optimization measures [5] Group 3: Product Development and Market Strategy - The company is diversifying its product portfolio, with new products like allulose and tagatose showing promising market potential [6][8] - Allulose production capacity has been established, with sales increasing significantly in the first nine months of the year [6] - The company is also focusing on developing new products for the cosmetics sector, leveraging its synthetic biology technology [6] Group 4: Cost Management and Raw Material Strategy - The company is transitioning to using liquid starch as a primary raw material to reduce costs and improve competitiveness [7] - A corn processing production line is under construction to further lower raw material costs and support compliance with EU trade regulations [7] Group 5: Future Plans and Market Expansion - The company plans to enhance its market presence in Southeast Asia, India, and the Middle East, with some regions showing increased demand that offsets fluctuations in the U.S. market [5] - There are ongoing discussions with potential clients in Japan regarding the regulatory registration of new products based on the company's offerings [7]

证券日报网讯 11月24日晚间，三元生物发布公告称，公司于近日收到公司首次公开发行股票并在创业 板上市的保荐机构中信建投证券股份有限公司（简称"中信建投"）出具的《中信建投证券股份有限公司 关于变更山东三元生物科技股份有限公司首次公开发行股票项目持续督导保荐代表人的函》，原保荐代 表人陈磊先生因工作变动原因，不再负责公司首次公开发行股票并在创业板上市的持续督导保荐工作。 为保证公司持续督导工作的有序进行，中信建投委派邵路伟先生接替陈磊先生担任公司持续督导保荐代 表人，继续履行相关职责。 （文章来源：证券日报） ...

特此公告 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于近日收到公司首次 公开发行股票并在创业板上市的保荐机构中信建投证券股份有限公司（以下简称 "中信建投"）出具的《中信建投证券股份有限公司关于变更山东三元生物科技 股份有限公司首次公开发行股票项目持续督导保荐代表人的函》，原保荐代表人 陈磊先生因工作变动原因，不再负责公司首次公开发行股票并在创业板上市的持 续督导保荐工作。 为保证公司持续督导工作的有序进行，中信建投委派邵路伟先生（简历详见 附件）接替陈磊先生担任公司持续督导保荐代表人，继续履行相关职责。本次保 荐代表人变更后，公司持续督导期保荐代表人为邵路伟先生和张现良先生。持续 督导期至 2025 年 12 月 31 日止。 公司董事会对陈磊先生在公司首次公开发行股票项目保荐发行及持续督导 期间所做的贡献表示衷心的感谢。 证券代码：301206 证券简称：三元生物 公告编号：2025-088 山东三元生物科技股份有限公司 山东三元生物科技股份有限公司 董事会 2025 年 1 ...